End-of-day quote
Other stock markets
|
||
- USD | - |
Sep. 14 | Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia | CI |
Sep. 13 | Moderna's Faces 'Material Headwinds' on RSV, COVID, RBC Says | MT |
Business description: Pfizer Inc
- primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.;
- specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.;
- oncology products (12.1%);
- other (1.3%).
At the end of 2022, the group had more than 35 manufacturing sites worldwide.
Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
Sales by Activity: Pfizer Inc
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Global Biopharmaceuticals Business (Biopharma) | 39.42B | 41.91B | 79.56B | 98.99B | 57.19B |
Upjohn | 10.23B | - | - | - | - |
Other business activities | 2.1B | - | 1.73B | 1.34B | 1.31B |
Geographical breakdown of sales: Pfizer Inc
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
United States | 23.85B | 21.71B | 29.75B | 42.47B | 27.09B |
Emerging Markets | 12.73B | 8.37B | 20.7B | 20.1B | 12B |
Developed Europe | 8.7B | 7.79B | 18.34B | 21.98B | 11.65B |
International | 6.46B | 4.04B | 12.51B | 15.78B | 7.76B |
Managers: Pfizer Inc
Director | Title | Age | Since |
---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 62 | 92-12-31 |
David Denton
DFI | Director of Finance/CFO | 59 | 22-05-01 |
Rady Johnson
CMP | Compliance Officer | 63 | 93-12-31 |
Aida Habtezion
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Maria Rivas
CTO | Chief Tech/Sci/R&D Officer | 60 | 22-08-31 |
Members of the board: Pfizer Inc
Manager | Title | Age | Since |
---|---|---|---|
Suzanne Johnson
BRD | Director/Board Member | 66 | 07-08-31 |
Helen Hobbs
BRD | Director/Board Member | 71 | 11-12-11 |
Shantanu Narayen
BRD | Director/Board Member | 60 | 13-09-26 |
Albert Bourla
CEO | Chief Executive Officer | 62 | 92-12-31 |
Jim Smith
BRD | Director/Board Member | 64 | 14-06-25 |
Director/Board Member | 66 | 15-06-24 | |
Ronald Blaylock
BRD | Director/Board Member | 64 | 17-02-22 |
Dan Littman
BRD | Director/Board Member | 71 | 18-03-04 |
Scott Gottlieb
BRD | Director/Board Member | 51 | 19-06-26 |
James Quincey
BRD | Director/Board Member | 59 | 20-02-26 |
Holdings: Pfizer Inc
Name | Equities | % | Valuation |
---|---|---|---|
HALEON PLC 32.39% | 2,955,063,626 | 32.39% | 14,835,719,631 $ |
PFIZER LIMITED 63.92% | 29,243,042 | 63.92% | 2,113,839,140 $ |
ARVINAS, INC. 5.04% | 3,457,815 | 5.04% | 90,456,440 $ |
AKERO THERAPEUTICS, INC. 3.64% | 2,525,252 | 3.64% | 68,686,854 $ |
ALLOGENE THERAPEUTICS, INC. 10.54% | 22,032,040 | 10.54% | 57,944,265 $ |
VALNEVA 6.86% | 9,549,761 | 6.86% | 34,777,365 $ |
PYXIS ONCOLOGY, INC. 11.93% | 7,032,770 | 11.93% | 26,654,198 $ |
CSTONE PHARMACEUTICALS 9.03% | 115,928,803 | 9.03% | 23,036,212 $ |
CSTONE PHARMACEUTICALS 4.96% | 1,272,214 | 4.96% | 21,436,806 $ |
NXERA PHARMA CO., LTD. 2.10% | 1,885,136 | 2.10% | 18,125,677 $ |
Company details: Pfizer Inc
Group companies: Pfizer Inc
Name | Category and Sector |
---|---|
Pfizer Export Co.
Pfizer Export Co. Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Pfizer Export Co. is an Irish company located in Cork. The firm develops and manufactures pharmaceutical products. |
Pharmaceuticals: Major
|
Pfizer Italia Srl
Pfizer Italia Srl Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Pfizer Italia Srl is a pharmaceutical company based in Latina, Italy. The Italian company manufactures pharmaceutical products. The company was founded in 1955. The CEO is Paivi Kerkola. |
Pharmaceuticals: Major
|
Viatris Netherlands BV
Viatris Netherlands BV Medical DistributorsDistribution Services Part of Viatris, Inc., Viatris Netherlands BV is a Dutch company that wholesales pharmaceutical, cosmetics, and perfumes and functions as a financial holding company. The company is located in the Netherlands. |
Medical Distributors
|
Pfizer Overseas LLC
| |
Pfizer Luxembourg SARL
|
Other Pharmaceuticals
Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
---|---|---|---|---|---|---|
-1.21% | +2.33% | +60.46% | +295.20% | 832B | ||
+0.47% | +4.20% | +37.81% | +188.65% | 605B | ||
+0.53% | +0.69% | +2.52% | +0.06% | 398B | ||
+0.10% | +0.42% | +27.67% | +80.21% | 343B | ||
+0.53% | -1.68% | +7.76% | +59.13% | 294B | ||
+0.99% | -3.14% | +1.63% | -22.72% | 252B | ||
-1.01% | -5.71% | +9.03% | +46.81% | 243B | ||
-0.28% | -0.45% | +6.39% | +25.44% | 234B | ||
+0.72% | +3.71% | +27.51% | +52.41% | 179B | ||
Average | +0.09% | +0.04% | +20.09% | +80.58% | 375.56B | |
Weighted average by Cap. | -0.08% | +0.82% | +28.09% | +125.90% |
- Stock Market
- Equities
- PFE Stock
- Stock
- Company Pfizer Inc